Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX)‘s stock had its “sector perform” rating reaffirmed by stock analysts at Royal Bank Of Canada in a research note issued on Wednesday. They presently have a C$23.00 price target on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 18.19% from the stock’s previous close.

Separately, TD Securities upped their price objective on shares of Valeant Pharmaceuticals Intl to C$26.00 and gave the company a “hold” rating in a report on Wednesday, July 12th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of C$22.50.

Valeant Pharmaceuticals Intl (TSE:VRX) opened at C$19.46 on Wednesday. Valeant Pharmaceuticals Intl has a fifty-two week low of C$11.20 and a fifty-two week high of C$25.38.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at

In related news, Director Schutter Richard Urbain De acquired 4,900 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were purchased at an average price of C$14.35 per share, for a total transaction of C$70,315.00.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.